Moderna to Seek Full FDA Approval This Month

Yesterday, Moderna announced it will be completing it’s application for full approval from the FDA this month. The company’s Covid-19 vaccine shows 93% efficacy against symptomatic disease through six months. The data came from a final analysis of the vaccine’s phase 3 study which enrolled thousands of participants who received both doses last year before the shot was available to everyone.

Trial participants received both vaccines before November 25th and were evaluated for 6 months following their doses before the Delta variant became dominant in the United States and spurred the current surge in cases. Last month, Pfizer released data which showed an overall six month efficacy of 91%, that was also collected before the Delta variant became prominent.